Ultime notizie per PureTech Health (NASDAQ:PRTC) Azioni

PureTech Health

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

PureTech Health plc - American Depositary Shares

PureTech Health PLC

INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) reported quarterly earnings of $0.00 per share. This is a 99.44 percent decrease over earnings of $0.18 per share from the same period last year. The company reported $58.33 million in sales this quarter. This is a 2.00 percent decrease over sales of $59.52 million the same period last year.

Earnings

News

INEO

INNEOVA Holdings FY24 EPS $0.0008 Down From $0.18 YoY, Sales $58.33M Down From $59.52M YoY

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.17%</li>
<li>Barclays analyst Gaurav Jain maintained an Overweight rating and raised the price target from $175 to $205 on May 2, 2025. This analyst has an accuracy rate of 65%.</li>
<li>JP Morgan analyst Jared Dinges maintained an Overweight rating and boosted the price target from $145 to $160 on Feb. 18, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On April 23, Philip Morris reported better-than-expected first-quarter financial results and raised its FY25 adjusted EPS guidance above estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest PM <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0519">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0519"><img loading="lazy" decoding="async" width="907" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032716/image-222.png" alt="" class="wp-image-919364" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032716/image-222.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032716/image-222-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032716/image-222-768x701.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.31%</li>
<li>Barclays analyst Lauren Lieberman maintained an Equal-Weight rating and cut the price target from $60 to $57 on May 12, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst Dara Mohsenian maintained an Equal-Weight rating and cut the price target from $63 to $58 on May 9, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On May 8, Molson Coors Beverage reported worse-than-expected first-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest TAP <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0519">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0519"><img loading="lazy" decoding="async" width="907" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032750/image-223.png" alt="" class="wp-image-919365" style="width:596px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032750/image-223.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032750/image-223-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032750/image-223-768x713.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.46%</li>
<li>Morgan Stanley analyst Megan Alexander maintained an Equal-Weight rating and cut the price target from $183 to $177 on April 17, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Wells Fargo analyst Chris Carey maintained an Underweight rating and raised the price target from $125 to $132 on March 14, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On May 1, Hershey posted upbeat quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest HSY <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0519">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0519"><img loading="lazy" decoding="async" width="912" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032827/image-224.png" alt="" class="wp-image-919366" style="width:706px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032827/image-224.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032827/image-224-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19032827/image-224-768x691.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45466164/jim-cramer-prefers-autozone-over-rival-buy-the-one-thats-not-going-to-stock-split">Jim Cramer Prefers AutoZone Over Rival: &#8216;Buy The One That&#8217;s Not Going To Stock Split&#8217;</a> </li>
</ul>
Photo via Shutterstock

Dividends

Price Target

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields

Wells Fargo analyst Blaine Heck maintains Douglas Emmett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEI#NYSE">DEI</a>) with a Overweight and lowers the price target from $20 to $16.

Wells Fargo Maintains Overweight on Douglas Emmett, Lowers Price Target to $16

UnitedHealth Group Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) <a href="https://www.benzinga.com/quote/UNH/news">recent nosedive wasn't just a chart pattern</a> — it was a conviction breaker. 
Tom Hulick, CEO of Strategy Asset Managers, didn't wait for a rebound. He dumped the stock, citing "a deterioration in fundamentals" in exclusive insights shared with Benizinga over email.
UnitedHealth&#8217;s stock is down over 42% year-to-date, over 31% down in the past month alone.
<h2 class="wp-block-heading">Asset Manager Walks Away From UNH Stock</h2>
The asset manager's exit from UnitedHealth stock followed a string of gut punches for UnitedHealth: an unexpected CEO resignation, fiscal 2025 guidance withdrawal, and what Hulick called "a rare earnings miss and downward revisions to EPS." But the real red flag?
A company that always looked forward suddenly stopped doing so. "When a perennial compounder stops providing forward guidance and leadership turnover coincides with performance slippage, it's a signal to pay attention."
Read Also: <a href="https://www.benzinga.com/general/health-care/25/05/45486314/unitedhealth-ceo-other-insiders-buy-millions-in-stock-as-it-sinks-over-23-in-a-week-move-gets-mixed-reaction">UnitedHealth CEO, Other Insiders Buy Millions In Stock As It Sinks Over 23% In A Week</a>
<h2 class="wp-block-heading">The Storm Brewing In Medicare Advantage</h2>
And Hulick's attention is now on a storm brewing in Medicare Advantage. Once UnitedHealth's profit engine, it's now showing signs of burnout. "Rising utilization, tighter reimbursement, and structural adjustments tied to the CMS risk model transition" have created a perfect storm, Hulick said, adding that "margin compression at a scale that can't be resolved with typical cost controls" could lead to slower growth or even retrenchment.
The broader picture isn't much rosier for the managed care sector. With regulators circling and medical loss ratios climbing, Hulick says the core business model is losing its shine. "The upside appears capped relative to prior cycles," he said, noting a shift in the defensive-growth balance that "is not necessarily in favor of the incumbents."
<h2 class="wp-block-heading">Going Long On Science, Instead</h2>
So where is the $700 million manager putting its chips? Hulick is going long on science. "We're investing in innovation-driven segments that offer idiosyncratic upside and aren't tethered to reimbursement dynamics."
That includes early-stage biotech, gene editing, and longevity plays &#8211; plus global insurance firms like Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>), which Hulick says have "demonstrated durable growth, pricing power, and operate in areas less exposed to the volatility we're seeing in U.S. health insurance."
UNH may be the canary in the managed care coal mine. While Hulick sees "rising costs, regulatory friction, and deteriorating visibility" across the sector, he singles out UnitedHealth as "uniquely exposed" given its size, complexity, and "integration challenges-especially with Optum."
The firm has exited UnitedHealth across three equity strategies but is holding onto bonds maturing in 2026 &#8211; one place where Hulick still sees strength. "The A+ rating and balance sheet strength remain intact."
But in equities, the message is clear: "The focus now is on innovation, not incumbency."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distortion">Trump&#8217;s Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight &#8216;Racket,&#8217; Pricing Distortion</a></li>
</ul>
Image: Shutterstock

Analyst Color

Health Care

Exclusives

Movers

Interview

General

EXCLUSIVE: UnitedHealth Gets Dumped, Why This Asset Manager Says Insurer Is No Longer A Safe Bet

INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) reported $58.30 million in sales this quarter. This is a 2.02 percent decrease over sales of $59.50 million the same period last year.

INNEOVA Holdings FY Sales $58.30M Down From $59.50M YoY

Guidance

Watching JP Morgan; Consumer And Community Banking CEO Marianne Lake Reportedly Says Credit Costs Remain In Line With Our Expectation For 2025; Consumers And Small Businesses Remain Resilient,  Consumer Confidence And Small Business Sentiment Have Worsened; We Expect Stronger Loan Growth Of 8% Or More For Credit Cards; Headcount Could Trend Down By 10% Over Next Five Years In Consumer Banking; We Have A Long Term Ambition To Double Wealth Management Business And Reach $2T In Total Client Assets

Macro Economic Events

Global

Economics

U.S. VP Vance Reportedly Says Talked With Pope On Range Of Diplomatic Issues; We Realize There Is A Bit Of An Impasse In Talks Over War In Ukraine; Putin Does Not Seem To Quite Know How To Get Out Of Ukraine War; If Russia Not Willing To Engage, Eventually U.S. Has To Say This Is Not Our War

Wells Fargo analyst Blaine Heck maintains Cousins Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUZ#NYSE">CUZ</a>) with a Overweight and lowers the price target from $34 to $32.

Wells Fargo Maintains Overweight on Cousins Props, Lowers Price Target to $32

On May 19, 2025, Talen Energy Corporation (the "Company," "we," "us," or "our") gave the following update regarding the ongoing maintenance outage at its Susquehanna Steam Electric Station ("Susquehanna"): In late March, Susquehanna commenced its planned refueling outage on Unit 2. In our May 8, 2025 earnings release and subsequent investor call, the Company provided an update about the outage and described incremental balance-of-plant maintenance in the extraction steam system that we expected would extend the outage into mid-May and add approximately $20 million in costs. We have now completed the underlying maintenance work and are addressing realignment and assembly that have required rework to pass quality testing. We are currently in the final stages of the process, focused on testing, final welds, and alignment verifications. To account for the remaining re-assembly tasks, we are updating the outage timeline from mid-May to the first week of June. The outage extension is now expected to increase expenses by approximately $35 million and we anticipate efficiency gains will pay back the additional costs and lost margin in roughly two years. The Company's financial guidance for 2025 remains unchanged.

Talen Energy Provides Update On Ongoing Susquehanna Steam Electric Station Outage, Extends Timeline To Early June Due To Additional Rework, Increases Cost Estimate By $35M; Expects Efficiency Gains To Offset Additional Costs And Lost Margin Within 2-Years, with 2025 Financial Guidance Unchanged

Wells Fargo analyst Blaine Heck maintains COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) with a Overweight and lowers the price target from $36 to $30.

Wells Fargo Maintains Overweight on COPT Defense Props, Lowers Price Target to $30

Management

Envoy Medical, Inc. - Class A Common Stock

COCH

Envoy Medical Says David R. Wells Steps Down As CFO; Brent T. Lucas To Serve As Interim CFO

8&#215;8, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) will release its fourth-quarter earnings results after the <a href="https://www.benzinga.com/quote/EGHT/earnings">closing bell on Monday, May 19</a>.
Analysts expect the Campbell, California-based company to report quarterly earnings at 8 cents per share, compared to 8 cents per share in the year-ago period. According to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, 8&#215;8 projects quarterly revenue at $177.98 million, compared to $179.41 million a year earlier.
On May 13, 8&#215;8 strengthened Irish market presence with expanded CCMA Ireland partnership.
8&#215;8 shares closed at $1.81 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/eght/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Rosenblatt analyst Catherine Trebnick maintained a Buy rating and cut the price target from $3.3 to $2.7 on April 24, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Wells Fargo analyst Michael Turrin maintained an Underweight rating and slashed the price target from $2 to $1.5 on April 22, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Morgan Stanley analyst Meta Marshall maintained an Underweight rating and cut the price target from $2.6 to $1.9 on April 16, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Mizuho analyst Siti Panigrahi maintained an Underperform rating and slashed the price target from $2.5 to $2 on April 15, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Barclays analyst Ryan Macwilliams maintained an Equal-Weight rating and raised the price target from $2.5 to $3 on Feb. 5, 2025. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying EGHT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/18081824/image-215-1024x589.png" alt="" class="wp-image-918903" style="width:664px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/18081824/image-215-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/18081824/image-215-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/18081824/image-215-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/18081824/image-215.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45466849/top-3-consumer-stocks-that-may-fall-off-a-cliff-in-q2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45466849/top-3-consumer-stocks-that-may-fall-off-a-cliff-in-q2">Top 3 Consumer Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Markets

EGHT

Top Wall Street Forecasters Revamp 8x8 Expectations Ahead Of Q4 Earnings

Offerings

QCOM

Qualcomm Files For Three-Part Notes Offering; Size Not Disclosed

Wedbush analyst Scott Devitt reiterates CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Outperform and maintains $90 price target.

Reiteration

Wedbush Reiterates Outperform on CarMax, Maintains $90 Price Target

<a href="https://www.mba.org/conferences-and-education/secondary-and-capital-markets-conference/schedule/session-detail/opening-general-session-economic-outlook-from-the-new-york-fed-79913" title="https://www.mba.org/conferences-and-education/secondary-and-capital-markets-conference/schedule/session-detail/opening-general-session-economic-outlook-from-the-new-york-fed-79913">https://www.mba.org/conferences-and-education/secondary-and-capital-markets-conference/schedule/session-detail/opening-general-session-economic-outlook-from-the-new-york-fed-79913</a>

Federal Reserve

Fed's Williams Says It's Going To Take Some Time To Get Good Read On Economy; Fed Can Take Its Time On Monetary Policy Decisions; Tariffs Potentially Raise Inflation And Unemployment

Wells Fargo analyst Blaine Heck maintains BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) with a Overweight and lowers the price target from $80 to $78.

Wells Fargo Maintains Overweight on BXP, Lowers Price Target to $78

<a href="https://www.federalreserve.gov/newsevents/speech/jefferson20250519a.htm" title="https://www.federalreserve.gov/newsevents/speech/jefferson20250519a.htm">https://www.federalreserve.gov/newsevents/speech/jefferson20250519a.htm</a>

Fed's Jefferson Says Will Keep Policy In A Place To Be Sure Inflation Expectations Remain Anchored; So Far The Labor Market Has Been Very Resilient; It Is Too Early To Tell How The Labor Market Will Be Effected By Administration Policies; There Are No Active Conversations About Changing The Ample Reserve Operating Framework

Fed's Jefferson Says The Impact Of Tariffs On The Fed's Mandates Is Top Of Mind; The Risks To The Fed's Mandates Depends On Policy Choices By The Administration That Have Not Been Made; There Are Risks To Both Jobs And Inflation, But Given Uncertainty It Is Appropriate To Wait And See On Rate Decisions; The U.S. Could Face A One-time Increase In The Price Level From Tariffs, Need To Be Sure That Does Not Become A Sustained Increase In Inflation

Wells Fargo analyst Blaine Heck maintains Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Equal-Weight and lowers the price target from $67 to $63.

TRNO

Wells Fargo Maintains Equal-Weight on Terreno Realty, Lowers Price Target to $63

<a href="https://www.youtube.com/watch?v=3KbNvXF1G7M" title="https://www.youtube.com/watch?v=3KbNvXF1G7M">https://www.youtube.com/watch?v=3KbNvXF1G7M</a>

White House On Moody's, Says World Has Confidence In U.S. Economy; President Trump Disagrees With Assessment

Press Releases

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

Comments

PureTech Health

Notizie

Ultime notizie per PureTech Health (NASDAQ:PRTC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO